KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables - Net (2016 - 2025)

Sarepta Therapeutics has reported Receivables - Net over the past 15 years, most recently at $398.2 million for Q4 2025.

  • Quarterly results put Receivables - Net at $398.2 million for Q4 2025, down 33.85% from a year ago — trailing twelve months through Dec 2025 was $398.2 million (down 33.85% YoY), and the annual figure for FY2025 was $398.2 million, down 33.85%.
  • Receivables - Net for Q4 2025 was $398.2 million at Sarepta Therapeutics, up from $395.7 million in the prior quarter.
  • Over the last five years, Receivables - Net for SRPT hit a ceiling of $659.4 million in Q1 2025 and a floor of $118.2 million in Q1 2021.
  • Median Receivables - Net over the past 5 years was $277.9 million (2023), compared with a mean of $314.1 million.
  • Biggest five-year swings in Receivables - Net: surged 86.55% in 2023 and later crashed 33.85% in 2025.
  • Sarepta Therapeutics' Receivables - Net stood at $153.0 million in 2021, then surged by 40.27% to $214.6 million in 2022, then surged by 86.55% to $400.3 million in 2023, then surged by 50.37% to $602.0 million in 2024, then crashed by 33.85% to $398.2 million in 2025.
  • The last three reported values for Receivables - Net were $398.2 million (Q4 2025), $395.7 million (Q3 2025), and $527.3 million (Q2 2025) per Business Quant data.